Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Fibrolamellar Carcinoma Treatment & Management

  • Author: Michael A Choti, MD, MBA, FACS; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
 
Updated: Sep 17, 2015
 

Medical Care

Surgical resection or transplantation is the standard of care for fibrolamellar carcinoma (FLC) for eligible patients. Trans-arterial chemo-embolization (TACE) may be a useful option in patients who have unresectable disease.[73, 74] Chemotherapy for metastatic disease is as for metastatic typical hepatocellular carcinoma (HCC). Single-agent chemotherapy or combinations of chemotherapeutic drugs give responses of no more than 25%, with questionable benefit for overall survival.

Sorafenib is an orally delivered small molecule that inhibits several different protein kinases, including Raf-1 and B-Raf, platelet-derived growth factor β (PDGFR-β), and vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. Sorafenib targets both tumor growth (Raf-MEK-ERK pathway) and neoangiogenesis (VEGFRs, PDGFR-β), both of which are thought to be important in the pathogenesis of typical hepatocellular carcinoma.

A randomized controlled trial of sorafenib in 602 patients with advanced typical hepatocellular carcinoma, and well-compensated cirrhosis demonstrated a survival benefit with sorafenib as compared with placebo, corresponding to a 3-month increase in median survival (10.7 versus 7.9 mo).[75]

A similar study will likely never be performed in fibrolamellar carcinoma due to the rarity of the disease. It is unclear whether the data on sorafenib for typical hepatocellular carcinoma are generalizable to fibrolamellar carcinoma. There are not yet any reports in the literature describing sorafenib use in fibrolamellar carcinoma.

A phase II clinical trial reported in 2003 evaluated 21-day courses of systemic continuous 5-fluorouracil repeated monthly and thrice-weekly subcutaneous recombinant interferon α-2b in a mixed population of 43 patients with fibrolamellar carcinoma and typical hepatocellular carcinoma.[76] All of these patients were ineligible for surgical therapy due to extent of hepatic disease as determined by CT scan, but none had extrahepatic disease. Of nine patients with fibrolamellar carcinoma, eight were radiologically assessed for response. Among these eight patients, there were one complete response (CR), four partial responses (PR), and one minor response (MR). The medial survival of the fibrolamellar carcinoma patients was 23 months, compared with 15.5 months for typical hepatocellular carcinoma (statistical significance not reported).

Of note, a major reason that the authors chose this treatment regimen was that they anticipated that it would be well tolerated by patients with cirrhosis. Although the regimen was well tolerated in this trial, none of the fibrolamellar carcinoma patients in fact had cirrhosis. Because fibrolamellar carcinoma patients generally do not have cirrhosis, chemotherapeutic regimens that might not appropriate for typical hepatocellular carcinoma might be of use in fibrolamellar carcinoma.

Pediatric Intergroup Hepatoma Protocol INT-0098 enrolled 46 patients with hepatocellular carcinoma from 1989-1992, of whom 10 had fibrolamellar carcinoma and the remainder typical hepatocellular carcinoma.[19] Of the 10 patients with fibrolamellar carcinoma, two initially underwent R0 resection, six underwent R2 resection, and two were found to have metastatic disease and underwent either debulking or biopsy.

Subsequently, seven of these patients (both R0, three R2, and two metastatic) received chemotherapy with cisplatin/doxorubicin, and three (all R2) received cisplatin/vincristine/doxorubicin. The median survival of the fibrolamellar carcinoma patients was 13.6 months, compared with 3.3 months for typical hepatocellular carcinoma patients. This difference was not statistically significant and should be cautiously interpreted due to the small sample size and because this was a subset analysis of a larger trial.

Next

Surgical Care

Optimal management for most hepatic malignancies, including typical hepatocellular carcinoma and fibrolamellar carcinoma, is complete surgical resection (eg, wedge resection, anatomic liver resection, or total hepatectomy with orthotopic liver transplantation). There may be occasional utility in treating fibrolamellar carcinoma with neoadjuvant chemotherapy or trans-arterial chemo-embolization (TACE) with the goal of downstaging the tumor to allow resection.[73]

Hepatic resection

Cirrhosis often limits the feasibility of liver resection in patients with typical hepatocellular carcinoma because cirrhotic patients have increased perioperative risk and require a larger future liver remnant (FLR) to be left behind to allow adequate liver function. In contrast, fibrolamellar carcinoma is rarely associated with cirrhosis, and patients are often young and otherwise healthy. For this reason, aggressive liver resections can be more readily undertaken in fibrolamellar carcinoma patients than in typical hepatocellular carcinoma patients.

Only a few modern surgical series of liver resection for fibrolamellar carcinoma have been published, as follows:

  • Pinna (1997) reported the results of 28 patients undergoing liver resection for fibrolamellar carcinoma, with survival greater than 85% at 3 years and greater than 80% at 5 years. Tumor recurrence was found in 18 patients. [68]
  • Kakar (2005) reported the results of 20 patients undergoing liver resection for fibrolamellar carcinoma and compared the results to those for typical hepatocellular carcinoma. Five-year survival was 45%, similar to that found in hepatocellular carcinoma without cirrhosis but significantly better than in hepatocellular carcinoma with cirrhosis. [21]
  • Stipa (2006) reported the results of 28 patients undergoing liver resection for fibrolamellar carcinoma, with median survival of 112 months (versus 37 months for typical hepatocellular carcinoma) and 5-year survival of 76% (versus 37% for typical hepatocellular carcinoma). Median recurrence-free survival was 33 months, and 5-year recurrence-free survival was 18%. [38]

Patients with resected fibrolamellar carcinoma generally have a prognosis similar to that for noncirrhotic patients with resected typical hepatocellular carcinoma.[21, 20] Aggressive surgical approaches, even for recurrent disease, can be undertaken with good results.[25]

Orthotopic liver transplantation

Total hepatectomy followed by orthotopic liver transplantation (OLT) should be considered in patients with unresectable fibrolamellar carcinoma that is confined to the liver. Reports of liver transplantation for fibrolamellar carcinoma are confined to small series, the most recent of which are summarized below:

  • Pichlmayr (1997) reported the results of a large series of liver transplants performed for hepatobiliary malignancies, including 124 for typical hepatocellular carcinoma and 8 for fibrolamellar carcinoma. Hepatocellular carcinoma patients in this series had 1-year, 5-year, and 10-year survival rates of 53%, 26%, and 19%, respectively. The median survival was 13 months. No difference in outcomes was seen in patients with hepatocellular carcinoma with and without cirrhosis. Patients with fibrolamellar carcinoma in this series had superior prognoses, with 1-year, 5-year, and 10-year survival of 63%, 38%, and 25%, respectively. The median survival was 35 months. [77]
  • Pinna (1997) reported the results of 13 liver transplants for fibrolamellar carcinoma, with survival of approximately 45% at 3 years and approximately 35% at 5 years. [68]
  • El-Gazzaz (2000) reported the results of nine liver transplants for fibrolamellar carcinoma, with 1-year, 3-year, and 5-year survival of 90%, 75%, and 50%, respectively. [26]

Even among patients who develop tumor recurrence, the time to recurrence is significantly longer in patients with fibrolamellar carcinoma than in those with typical hepatocellular carcinoma.[78] This may be a result of more indolent behavior by fibrolamellar carcinoma versus typical hepatocellular carcinoma. Alternatively, it may result from the fact that accompanying cirrhosis in typical hepatocellular carcinoma increases the risk of recurrence (including development of a second primary tumor) via a field effect.

Orthotopic liver transplantation can result in long-term survival but is a resource-intensive treatment approach. In typical hepatocellular carcinoma, orthotopic liver transplantation confers the advantage of removing the at-risk cirrhotic liver in addition to the tumor itself. In fibrolamellar carcinoma, this theoretical advantage is likely not present because there is no such field effect at work (due to the lack of cirrhosis in most cases).

As such, it is not clear that the use of donor organs in patients with fibrolamellar carcinoma is an appropriate use of this scarce resource.[75] Newer innovative approaches (eg, adult living-related donations, split-liver techniques, and potential use of marginal donor organs) may allow for a future increase in the use of orthotopic liver transplantation for fibrolamellar carcinoma.

Previous
 
 
Contributor Information and Disclosures
Author

Michael A Choti, MD, MBA, FACS Hall and Mary Lucile Shannon Professor and Chair, Department of Surgery, University of Texas Southwestern Medical Center

Michael A Choti, MD, MBA, FACS is a member of the following medical societies: American Association for the Study of Liver Diseases, American Surgical Association, International Hepato-Pancreato-Biliary Association, Americas Hepato-Pancreato-Biliary Association, American Society of Clinical Oncology, American College of Surgeons, Association for Academic Surgery, Society for Surgery of the Alimentary Tract, Society of Surgical Oncology, Society of University Surgeons

Disclosure: Nothing to disclose.

Coauthor(s)

Hari Nathan, MD House Staff, Department of Surgery, The Johns Hopkins Hospital; Postdoctoral Fellow, Department of Surgery, The Johns Hopkins University School of Medicine

Hari Nathan, MD is a member of the following medical societies: American College of Surgeons, Association for Academic Surgery, Society for Surgery of the Alimentary Tract, Americas Hepato-Pancreato-Biliary Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

N Joseph Espat, MD, MS, FACS Harold J Wanebo Professor of Surgery, Assistant Dean of Clinical Affairs, Boston University School of Medicine; Chairman, Department of Surgery, Director, Adele R Decof Cancer Center, Roger Williams Medical Center

N Joseph Espat, MD, MS, FACS is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Parenteral and Enteral Nutrition, American Society of Clinical Oncology, Americas Hepato-Pancreato-Biliary Association, Association for Academic Surgery, Central Surgical Association, Chicago Medical Society, International Hepato-Pancreato-Biliary Association, Pancreas Club, Sigma Xi, Society for Leukocyte Biology, Society for Surgery of the Alimentary Tract, Society of American Gastrointestinal and Endoscopic Surgeons, Society of Surgical Oncology, Society of University Surgeons, Southeastern Surgical Congress, Southern Medical Association, Surgical Infection Society

Disclosure: Nothing to disclose.

Additional Contributors

Lodovico Balducci, MD Professor, Oncology Fellowship Director, Department of Internal Medicine, Division of Adult Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine

Lodovico Balducci, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association for Cancer Research, American College of Physicians, American Geriatrics Society, American Society of Hematology, New York Academy of Sciences, American Society of Clinical Oncology, Southern Society for Clinical Investigation, International Society for Experimental Hematology, American Federation for Clinical Research, American Society of Breast Disease

Disclosure: Nothing to disclose.

References
  1. Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956 Feb. 91(2):168-86. [Medline].

  2. Craig JR, Peters RL, Edmondson HA, et al. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980 Jul 15. 46(2):372-9. [Medline].

  3. Berman MM, Libbey NP, Foster JH. Hepatocellular carcinoma. Polygonal cell type with fibrous stroma--an atypical variant with a favorable prognosis. Cancer. 1980 Sep 15. 46(6):1448-55. [Medline].

  4. Farhi DC, Shikes RH, Murari PJ, et al. Hepatocellular carcinoma in young people. Cancer. 1983 Oct 15. 52(8):1516-25. [Medline].

  5. Stromeyer FW, Ishak KG, Gerber MA, et al. Ground-glass cells in hepatocellular carcinoma. Am J Clin Pathol. 1980 Sep. 74(3):254-8. [Medline].

  6. Klein WM, Molmenti EP, Colombani PM, et al. Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol. 2005 Oct. 124(4):512-8. [Medline].

  7. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol. 2007 May. 14(3):217-23. [Medline].

  8. Kannangai R, Vivekanandan P, Martinez-Murillo F, et al. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol. 2007 Apr. 38(4):639-44. [Medline].

  9. Vivekanandan P, Torbenson M. Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod Pathol. 2008 Jun. 21(6):670-5. [Medline].

  10. Ward SC, Waxman S. Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis. 2011 Feb. 31(1):61-70. [Medline].

  11. Farhi DC, Shikes RH, Silverberg SG. Ultrastructure of fibrolamellar oncocytic hepatoma. Cancer. 1982 Aug 15. 50(4):702-9. [Medline].

  12. Saul SH, Titelbaum DS, Gansler TS, et al. The fibrolamellar variant of hepatocellular carcinoma. Its association with focal nodular hyperplasia. Cancer. 1987 Dec 15. 60(12):3049-55. [Medline].

  13. Imkie M, Myers SA, Li Y, et al. Fibrolamellar hepatocellular carcinoma arising in a background of focal nodular hyperplasia: a report of 2 cases. J Reprod Med. 2005 Aug. 50(8):633-7. [Medline].

  14. Vecchio FM, Fabiano A, Ghirlanda G, et al. Fibrolamellar carcinoma of the liver: the malignant counterpart of focal nodular hyperplasia with oncocytic change. Am J Clin Pathol. 1984 Apr. 81(4):521-6. [Medline].

  15. Vecchio FM. Fibrolamellar carcinoma of the liver: a distinct entity within the hepatocellular tumors. A review. Appl Pathol. 1988. 6(2):139-48. [Medline].

  16. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004 Mar. 39(3):798-803. [Medline].

  17. Arista-Nasr J, Gutierrez-Villalobos L, Nuncio J, et al. Fibrolamellar hepatocellular carcinoma in mexican patients. Pathol Oncol Res. 2002. 8(2):133-7. [Medline].

  18. Haas JE, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer. 1989 Sep 1. 64(5):1082-95. [Medline].

  19. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003 Apr 15. 97(8):2006-12. [Medline].

  20. Nagorney DM, Adson MA, Weiland LH, et al. Fibrolamellar hepatoma. Am J Surg. 1985 Jan. 149(1):113-9. [Medline].

  21. Kakar S, Burgart LJ, Batts KP, et al. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 2005 Nov. 18(11):1417-23. [Medline].

  22. Mayo SC, Mavros MN, Nathan H, Cosgrove D, Herman JM, Kamel I, et al. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J Am Coll Surg. 2014 Feb. 218(2):196-205. [Medline].

  23. Groeschl RT, Miura JT, Wong RK, Bloomston M, Lidsky ML, Clary BM, et al. Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma. J Surg Oncol. 2014 Sep. 110(4):412-5. [Medline].

  24. Saab S, Yao F. Fibrolamellar hepatocellular carcinoma. Case reports and a review of the literature. Dig Dis Sci. 1996 Oct. 41(10):1981-5. [Medline].

  25. Hemming AW, Langer B, Sheiner P, et al. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg. 1997 Jul-Aug. 1(4):342-6. [Medline].

  26. El-Gazzaz G, Wong W, El-Hadary MK, et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int. 2000. 13 Suppl 1:S406-9. [Medline].

  27. Kanai T, Takabayashi T, Kawano Y, et al. A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacity in a young Japanese female. Jpn J Clin Oncol. 2004 Jun. 34(6):346-51. [Medline].

  28. Debray D, Pariente D, Fabre M, et al. Fibrolamellar hepatocellular carcinoma: report of a case mimicking a liver abscess. J Pediatr Gastroenterol Nutr. 1994 Nov. 19(4):468-72. [Medline].

  29. Soyer P, Roche A, Levesque M. Fibrolamellar hepatocellular carcinoma presenting with obstructive jaundice. A report of two cases. Eur J Radiol. 1991 Nov-Dec. 13(3):196-8. [Medline].

  30. Eckstein RP, Bambach CP, Stiel D, et al. Fibrolamellar carcinoma as a cause of bile duct obstruction. Pathology. 1988 Oct. 20(4):326-31. [Medline].

  31. Agarwal VR, Takayama K, Van Wyk JJ, et al. Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J Clin Endocrinol Metab. 1998 May. 83(5):1797-800. [Medline].

  32. McCloskey JJ, Germain-Lee EL, Perman JA, et al. Gynecomastia as a presenting sign of fibrolamellar carcinoma of the liver. Pediatrics. 1988 Sep. 82(3):379-82. [Medline].

  33. Buetow PC, Pantongrag-Brown L, Buck JL, et al. Focal nodular hyperplasia of the liver: radiologic-pathologic correlation. Radiographics. 1996 Mar. 16(2):369-88. [Medline].

  34. Okada K, Kim YI, Nakashima K, et al. Fibrolamellar hepatocellular carcinoma coexistent with a hepatocellular carcinoma of common type: report of a case. Surg Today. 1993. 23(7):626-31. [Medline].

  35. Okano A, Hajiro K, Takakuwa H, et al. Fibrolamellar carcinoma of the liver with a mixture of ordinary hepatocellular carcinoma: a case report. Am J Gastroenterol. 1998 Jul. 93(7):1144-5. [Medline].

  36. Seitz G, Zimmermann A, Friess H, Büchler MW. Adult-type hepatocellular carcinoma in the center of a fibrolamellar hepatocellular carcinoma. Hum Pathol. 2002 Jul. 33(7):765-9. [Medline].

  37. Morise Z, Sugioka A, Mizoguchi Y, et al. Fibrolamellar carcinoma of the liver in a Japanese hepatitis B virus carrier. J Gastroenterol Hepatol. 2005 Jul. 20(7):1136-8. [Medline].

  38. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006 Mar 15. 106(6):1331-8. [Medline].

  39. Yamamoto H, Watanabe K, Nagata M, et al. Transformation of fibrolamellar carcinoma to common hepatocellular carcinoma in the recurrent lesions of the rectum and the residual liver: a case report. Jpn J Clin Oncol. 1999 Sep. 29(9):445-7. [Medline].

  40. Chang YC, Dai YC, Chow NH. Fibrolamellar hepatocellular carcinoma with a recurrence of classic hepatocellular carcinoma: a case report and review of Oriental cases. Hepatogastroenterology. 2003 Sep-Oct. 50(53):1637-40. [Medline].

  41. Tanaka K, Honna T, Kitano Y, et al. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report. J Clin Pathol. 2005 Aug. 58(8):884-7. [Medline].

  42. Ichikawa T, Federle MP, Grazioli L, et al. Fibrolamellar hepatocellular carcinoma: pre- and posttherapy evaluation with CT and MR imaging. Radiology. 2000 Oct. 217(1):145-51. [Medline].

  43. Paradinas FJ, Melia WM, Wilkinson ML, et al. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed). 1982 Sep 25. 285(6345):840-2. [Medline].

  44. Sheppard KJ, Bradbury DA, Davies JM, et al. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed). 1983 Jan 1. 286(6358):57. [Medline].

  45. Collier NA, Weinbren K, Bloom SR, et al. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet. 1984 Mar 10. 1(8376):538-40. [Medline].

  46. Brandt DJ, Johnson CD, Stephens DH, et al. Imaging of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol. 1988 Aug. 151(2):295-9. [Medline].

  47. Corrigan K, Semelka RC. Dynamic contrast-enhanced MR imaging of fibrolamellar hepatocellular carcinoma. Abdom Imaging. 1995 Mar-Apr. 20(2):122-5. [Medline].

  48. Gabata T, Matsui O, Kadoya M, et al. Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdom Imaging. 1998 May-Jun. 23(3):309-13. [Medline].

  49. Soyer P, Roche A, Levesque M, et al. CT of fibrolamellar hepatocellular carcinoma. J Comput Assist Tomogr. 1991 Jul-Aug. 15(4):533-8. [Medline].

  50. Soyer P, Bluemke DA, Vissuzaine C, et al. CT of hepatic tumors: prevalence and specificity of retraction of the adjacent liver capsule. AJR Am J Roentgenol. 1994 May. 162(5):1119-22. [Medline].

  51. Blachar A, Federle MP, Ferris JV, et al. Radiologists' performance in the diagnosis of liver tumors with central scars by using specific CT criteria. Radiology. 2002 May. 223(2):532-9. [Medline].

  52. Titelbaum DS, Hatabu H, Schiebler ML, et al. Fibrolamellar hepatocellular carcinoma: MR appearance. J Comput Assist Tomogr. 1988 Jul-Aug. 12(4):588-91. [Medline].

  53. Hamrick-Turner JE, Shipkey FH, Cranston PE. Fibrolamellar hepatocellular carcinoma: MR appearance mimicking focal nodular hyperplasia. J Comput Assist Tomogr. 1994 Mar-Apr. 18(2):301-4. [Medline].

  54. Hui MS, Choi WM, Perng HL, et al. Fibrolamellar hepatocellular carcinoma--an atypical MR manifestation. Hepatogastroenterology. 1998 Mar-Apr. 45(20):514-7. [Medline].

  55. Adam A, Gibson RN, Soreide O, et al. The radiology of fibrolamellar hepatoma. Clin Radiol. 1986 Jul. 37(4):355-8. [Medline].

  56. Miller WJ, Federle MP, Campbell WL. Diagnosis and staging of hepatocellular carcinoma: comparison of CT and sonography in 36 liver transplantation patients. AJR Am J Roentgenol. 1991 Aug. 157(2):303-6. [Medline].

  57. Stevens WR, Johnson CD, Stephens DH, et al. Fibrolamellar hepatocellular carcinoma: stage at presentation and results of aggressive surgical management. AJR Am J Roentgenol. 1995 May. 164(5):1153-8. [Medline].

  58. Stevens WR, Johnson CD, Stephens DH, et al. CT findings in hepatocellular carcinoma: correlation of tumor characteristics with causative factors, tumor size, and histologic tumor grade. Radiology. 1994 May. 191(2):531-7. [Medline].

  59. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999 Nov. 94(11):3314-9. [Medline].

  60. von Falck C, Rodt T, Shin HO, et al. F-18 FDG PET imaging of fibrolamellar hepatocellular carcinoma. Clin Nucl Med. 2008 Sep. 33(9):633-4. [Medline].

  61. Liu S, Wah Chan K, Tong J, Wang Y, Wang B, Qiao L. PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: a case report and a summary of recent literature. QJM. 2011 Jun. 104(6):477-83. [Medline].

  62. Crowe A, Knight CS, Jhala D, Bynon SJ, Jhala NC. Diagnosis of metastatic fibrolamellar hepatocellular carcinoma by endoscopic ultrasound-guided fine needle aspiration. Cytojournal. 2011 Jan 31. 8:2. [Medline]. [Full Text].

  63. Suen KC, Magee JF, Halparin LS, et al. Fine needle aspiration cytology of fibrolamellar hepatocellular carcinoma. Acta Cytol. 1985 Sep-Oct. 29(5):867-72. [Medline].

  64. Davenport RD. Cytologic diagnosis of fibrolamellar carcinoma of the liver by fine-needle aspiration. Diagn Cytopathol. 1990. 6(4):275-9. [Medline].

  65. Perez-Guillermo M, Masgrau NA, García-Solano J, et al. Cytologic aspect of fibrolamellar hepatocellular carcinoma in fine-needle aspirates. Diagn Cytopathol. 1999 Sep. 21(3):180-7. [Medline].

  66. Kojiro M. Histopathology of liver cancers. Best Pract Res Clin Gastroenterol. 2005 Feb. 19(1):39-62. [Medline].

  67. Mansouri D, Van Nhieu JT, Couanet D, et al. Fibrolamellar hepatocellular carcinoma: a case report with cytological features in a sixteen-year-old girl. Diagn Cytopathol. 2006 Aug. 34(8):568-71. [Medline].

  68. Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997 Oct. 26(4):877-83. [Medline].

  69. Ichikawa T, Federle MP, Grazioli L, et al. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology. 1999 Nov. 213(2):352-61. [Medline].

  70. Pan Y, Wang ZM, Mou LJ, et al. Focal nodular hyperplasia of the liver: pathological analysis of 11 cases. Hepatobiliary Pancreat Dis Int. 2004 May. 3(2):199-203. [Medline].

  71. Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. 1988 Jul. 19(7):784-94. [Medline].

  72. Vasdev N, Nayak NC. CD99 expression in hepatocellular carcinoma: an immunohistochemical study in the fibrolamellar and common variant of the tumour. Indian J Pathol Microbiol. 2003 Oct. 46(4):625-9. [Medline].

  73. Sitzmann JV. Conversion of unresectable to resectable liver cancer: an approach and follow-up study. World J Surg. 1995 Nov-Dec. 19(6):790-4. [Medline].

  74. Soyer P, Roche A, Rougier P, et al. [Nonresectable fibrolamellar hepatocellular carcinoma: outcome of 4 cases treated by intra-arterial chemotherapy]. J Belge Radiol. 1992 Dec. 75(6):463-8. [Medline].

  75. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24. 359(4):378-90. [Medline].

  76. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003 Feb 1. 21(3):421-7. [Medline].

  77. Pichlmayr R, Weimann A, Tusch G, et al. Indications and Role of Liver Transplantation for Malignant Tumors. Oncologist. 1997. 2(3):164-170. [Medline].

  78. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999 Jan. 17(1):324-31. [Medline].

  79. Bartlett D, Di Bisceglie A, Dawson L. Cancer of the Liver. De Vita VT, Lawrence TS, Rosenberg S. Cancer: Principles & Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott, Williams and Wilkins; 2008. 1: 1129-56.

  80. Epstein BE, Pajak TF, Haulk TL, et al. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol. 1999 Feb. 22(1):22-8. [Medline].

  81. Friedman AC, Lichtenstein JE, Goodman Z, et al. Fibrolamellar hepatocellular carcinoma. Radiology. 1985 Dec. 157(3):583-7. [Medline].

  82. Lamberts R, Nitsche R, de Vivie RE, et al. Budd-Chiari syndrome as the primary manifestation of a fibrolamellar hepatocellular carcinoma. Digestion. 1992. 53(3-4):200-9. [Medline].

  83. McLarney JK, Rucker PT, Bender GN, et al. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics. 1999 Mar-Apr. 19(2):453-71. [Medline].

  84. Steinmüller T, Jonas S, Neuhaus P. Review article: liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2003 Jun. 17 Suppl 2:138-44. [Medline].

 
Previous
Next
 
Fibrolamellar carcinoma: Note the large tumor size in the background of a noncirrhotic liver.
CT scan showing fibrolamellar carcinoma with a large stellate central scar.
T1-weighted MRI of a fibrolamellar carcinoma in the left lobe of the liver.
T2-weighted MRI of a fibrolamellar carcinoma in the left lobe of the liver, demonstrating a heterogeneous appearance with a central scar.
Hematoxylin and eosin photomicrograph of fibrolamellar carcinoma. Note the thick fibrous lamellae within the tumor stroma.
Masson trichrome stain photomicrograph of fibrolamellar carcinoma depicting the collagen-containing lamellae within the tumor stroma.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.